<DOC>
	<DOCNO>NCT02687152</DOCNO>
	<brief_summary>The present project design test hypothesis arginase contribute microvascular endothelial dysfunction patient type 2 diabetes microvascular complication .</brief_summary>
	<brief_title>Arginase Inhibition Microvascular Endothelial Function Type 2 Diabetes</brief_title>
	<detailed_description>Background The development microvascular complication diabetes complex process , endothelial dysfunction importance . Emerging evidence suggest arginase key mediator endothelial dysfunction type 2 diabetes mellitus ( T2DM ) reciprocally regulate nitric oxide bioavailability . The aim study test hypothesis arginase activity increase arginase contributes microvascular endothelial function patient T2DM microvascular dysfunction . Method Microvascular endothelium-dependent -independent vasodilatation investigate patient T2DM ( n =12 ) healthy age-matched control subject ( n =12 ) laser-Doppler flowmetry iontophoretic application acetylcholine sodium nitroprusside , respectively , intra-arterial administration arginase inhibitor N-hydroxy-nor-L-arginine ( 0.1 mg/min ) 120 min .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Clinical diagnosis type 2 diabetes mellitus microvascular dysfunction define microalbuminuria &gt; 3.0 mg/mmol presence retinopathy . Myocardial infarction unstable angina within last three month , Changed dose vasodilator drug precede six week , Ongoing treatment warfarin Concomitant disease may interfere possibility patient comply complete study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>